Department of Dermatology, Northwest Hospital, The Second Hospital Affiliated to Xi'an Jiaotong University, Xi'an, China.
School of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Contact Dermatitis. 2019 Sep;81(3):184-193. doi: 10.1111/cod.13292. Epub 2019 May 22.
Retinoic acid (RA)-induced dermatitis is the most frequent side-effect limiting its widespread use. However, the exact mechanisms triggering dermatitis are not fully understood, including the role of skin mast cells. The newly discovered Mas-related G-protein-coupled receptor-X2 (MRGPRX2) in mast cells mediates pseudoallergic drug reactions in several types of dermatitis. A possible contribution of MRGPRX2 to contact dermatitis induced by RA has hitherto not been examined.
To investigate whether all-trans-RA (ATRA) activates mast cells via MRGPRX2/MrgprB2 (the mouse orthologue), contributing to the pathogenesis of retinoid-induced dermatitis.
Wild-type (WT) and MrgprB2 mice were treated with topical ATRA to observe local inflammation and mast cell degranulation in vivo by the use of haematoxylin and eosin and immunofluorescence staining. Release of histamine and release of β-hexosaminidase were measured and calcium influx was detected in Laboratory of Allergic Disease 2 (LAD2) cells with specific knockdown targeting MRGPRX2 by small interfering RNA (siRNA) and in primary cells from MrgprB2 mice.
As compared with WT mice, MrgprB2 mice showed resistance to ATRA-triggered contact dermatitis and local inflammatory reactions in the paws. ATRA activated mast cells via the MrgprB2 pathway in murine cells, and via the MRGPRX2 pathway in human mast cells.
ATRA-induced dermatitis could be achieved by activating mast cells via MRGPRX2/MrgprB2, which may provide a potential therapy target to reduce the side-effect.
维甲酸(RA)诱导的皮炎是最常见的限制其广泛应用的副作用。然而,触发皮炎的确切机制尚不完全清楚,包括皮肤肥大细胞的作用。新发现的肥大细胞中的 Mas 相关 G 蛋白偶联受体-X2(MRGPRX2)介导几种类型皮炎中的假性过敏药物反应。MRGPRX2 对 RA 诱导的接触性皮炎的可能贡献迄今尚未被研究。
研究全反式维甲酸(ATRA)是否通过 MRGPRX2/MrgprB2(小鼠同源物)激活肥大细胞,从而导致类视黄醇诱导的皮炎发病机制。
用 ATLA 处理野生型(WT)和 MrgprB2 小鼠,通过苏木精和伊红以及免疫荧光染色在体内观察局部炎症和肥大细胞脱颗粒。通过使用特异性靶向 MRGPRX2 的小干扰 RNA(siRNA)在实验室过敏疾病 2 号(LAD2)细胞中和从 MrgprB2 小鼠分离的原代细胞中测量组胺释放和β-己糖胺酶释放,并检测钙内流。
与 WT 小鼠相比,MrgprB2 小鼠对 ATRA 触发的接触性皮炎和爪子中的局部炎症反应具有抗性。ATRA 通过 MrgprB2 途径在鼠细胞中激活肥大细胞,并通过 MRGPRX2 途径在人肥大细胞中激活肥大细胞。
通过激活 MRGPRX2/MrgprB2 可实现 ATRA 诱导的皮炎,这可能为减少副作用提供潜在的治疗靶点。